{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:08:49Z","timestamp":1780398529051,"version":"3.54.1"},"reference-count":119,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.berh.2025.102107","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T12:01:04Z","timestamp":1762689664000},"page":"102107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging therapies in idiopathic inflammatory myopathies: Advances in treatment and future directions"],"prefix":"10.1016","volume":"39","author":[{"given":"Laure","family":"Gallay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eaman","family":"Alhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niladri","family":"Bhowmick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/art.41964","article-title":"Performance of the 2017 European alliance of associations for Rheumatology\/American College of Rheumatology classification criteria for idiopathic inflammatory myopathies in patients with myositis-specific autoantibodies","volume":"74","author":"Casal-Dominguez","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/nan.12380","article-title":"Integrated classification of inflammatory myopathies","volume":"43","author":"Allenbach","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.12955","article-title":"The role of interferons type I, II and III in myositis: a review","volume":"31","author":"Bolko","year":"2021","journal-title":"Brain Pathol"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","article-title":"Dermatomyositis and type 1 interferons","volume":"12","author":"Greenberg","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2025.102107_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coi.2017.09.003","article-title":"Type I interferon-mediated autoinflammation and autoimmunity","volume":"49","author":"Kretschmer","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.berh.2025.102107_bib7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3389\/fimmu.2014.00342","article-title":"Pattern recognition and signaling mechanisms of RIG-I and MDA5","volume":"5","author":"Reikine","year":"2014","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jbspin.2019.09.005","article-title":"Inhibition of JAK\/STAT signaling in rheumatologic disorders: the expanding spectrum","volume":"87","author":"El","year":"2020","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.berh.2025.102107_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152426","article-title":"Treatment with Janus kinase inhibitors in juvenile dermatomyositis: a review of the literature","volume":"66","author":"Sener","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib12","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2025.102107_bib13","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.berh.2025.102107_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","article-title":"Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib","volume":"58","author":"Moghadam-Kia","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.berh.2025.102107_bib15","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/ajd.14335","article-title":"JAK inhibitors in refractory dermatomyositis: a case series","volume":"65","author":"Corbella-Bagot","year":"2024","journal-title":"Australas J Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2025.102107_bib17","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jaad.2022.08.025","article-title":"Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open-label study","volume":"87","author":"Zhao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.berh.2025.102107_bib18","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1093\/rheumatology\/keaa184","article-title":"Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis","volume":"59","author":"Delvino","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.annder.2023.03.008","article-title":"Efficacy of Janus kinase 1 and 2 inhibitor baricitinib in multirefractory cutaneous dermatomyositis","volume":"150","author":"Karaa","year":"2023","journal-title":"Ann Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.berh.2025.102107_bib20","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1093\/rheumatology\/keac084","article-title":"Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata","volume":"61","author":"Chen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib21","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1093\/rheumatology\/kead357","article-title":"Baricitinib rapidly improves mechanic's hands and hiker's feet in anti-synthetase syndrome","volume":"63","author":"Hu","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"10.1016\/j.berh.2025.102107_bib22","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2025.102107_bib23","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3481","article-title":"Unexpected hair regrowth in a patient with longstanding alopecia universalis during treatment of recalcitrant dermatomyositis with the janus kinase inhibitor ruxolitinib","volume":"100","author":"Fetter","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.berh.2025.102107_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jdcr.2023.09.043","article-title":"Efficacy of topical ruxolitinib for cutaneous dermatomyositis","volume":"45","author":"Lanis","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib25","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003837","article-title":"Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients","volume":"10","author":"Beckett","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2391445","article-title":"A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib","volume":"35","author":"Huang","year":"2024","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.berh.2025.102107_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jdcr.2024.08.047","article-title":"Case of recalcitrant amyopathic dermatomyositis treated with upadacitinib","volume":"54","author":"Zhou","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","article-title":"Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease","volume":"44","author":"Harada","year":"2024","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.berh.2025.102107_bib30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10928-024-09901-2","article-title":"Employing zero-inflated beta distribution in an exposure-response analysis of TYK2\/JAK1 inhibitor brepocitinib in patients with plaque psoriasis","volume":"51","author":"Tsamandouras","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"10.1016\/j.berh.2025.102107_bib32","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.berh.2025.102107_bib33","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ibd\/izab135","article-title":"Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise","volume":"27","author":"Danese","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib34","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300155","article-title":"Brepocitinib, zimlovisertib, and ropsacitinib in Hidradenitis suppurativa","volume":"3","author":"Kimball","year":"2024","journal-title":"NEJM Evid"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamadermatol.2023.4744","article-title":"Rapid improvement in recalcitrant cutaneous juvenile dermatomyositis with anifrolumab treatment","volume":"160","author":"Shaw","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2025.102107_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.10.023","article-title":"Refractory dermatomyositis responsive to anifrolumab","volume":"43","author":"Ang","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11792","article-title":"Recalcitrant dermatomyositis treated with anifrolumab","volume":"7","author":"Chaudhary","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.berh.2025.102107_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.17675","article-title":"Successful treatment of refractory cutaneous dermatomyositis with anifrolumab","author":"Helm","year":"2025","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2025.102107_bib39","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/ced\/llae476","article-title":"Anifrolumab use in refractory dermatomyositis: a case report and literature review","volume":"50","author":"Claudio-Oliva","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.berh.2025.102107_bib40","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljaf064","article-title":"Improvement in dermatomyositis-associated muscle disease with anifrolumab","author":"Shayegan","year":"2025","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102107_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jaad.2024.07.1491","article-title":"Anifrolumab in recalcitrant cutaneous dermatomyositis: a multicenter retrospective cohort study","volume":"91","author":"Shaw","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"10473","key":"10.1016\/j.berh.2025.102107_bib42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(24)02859-9","article-title":"Targeting IFN\u03b2 in dermatomyositis","volume":"405","author":"Benhadou","year":"2025","journal-title":"Lancet"},{"issue":"10473","key":"10.1016\/j.berh.2025.102107_bib43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(24)02071-3","article-title":"Efficacy, safety, and target engagement of dazukibart, an IFN\u03b2 specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Fiorentino","year":"2025","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.berh.2025.102107_bib44","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41423-024-01167-5","article-title":"The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond","volume":"21","author":"Ngo","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2044-5040-3-13","article-title":"Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness","volume":"3","author":"Rayavarapu","year":"2013","journal-title":"Skelet Muscle"},{"issue":"6","key":"10.1016\/j.berh.2025.102107_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103334","article-title":"The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review","volume":"22","author":"Gasparotto","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2025.102107_bib47","article-title":"29 Plasmacytoid dendritic cells as a treatment target","volume":"10","author":"Furie","year":"2025","journal-title":"Lupus Sci Med"},{"issue":"595","key":"10.1016\/j.berh.2025.102107_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf8442","article-title":"Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus","volume":"13","author":"Karnell","year":"2021","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.berh.2025.102107_bib49","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1136\/annrheumdis-2015-208119","article-title":"Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups","volume":"75","author":"Rothwell","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2025.102107_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/ar4116","article-title":"T cells in myositis","volume":"14","author":"Malmstr\u00f6m","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.berh.2025.102107_bib51","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202217240","article-title":"Single\u2010cell profiling of muscle\u2010infiltrating T cells in idiopathic inflammatory myopathies","volume":"15","author":"Argyriou","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib53","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reuma.2011.08.002","article-title":"Abatacept mechanism of action: concordance with its clinical profile","volume":"8","author":"Herrero-Beaumont","year":"2012","journal-title":"Reumatol Clin"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2025.102107_bib55","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/art.42450","article-title":"Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy","volume":"75","author":"Curiel","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2025.102107_bib56","article-title":"Efficacy and safety of subcutaneous abatacept plus standard treatment for active idiopathic inflammatory myopathy: phase 3 randomized controlled trial","author":"Aggarwal","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2025.102107_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf218","article-title":"Abatacept for the treatment of myositis-associated interstitial lung disease","author":"Aggarwal","year":"2025","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib58","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.chest.2017.12.010","article-title":"Sj\u00f6gren syndrome with associated lymphocytic interstitial pneumonia successfully treated with tacrolimus and abatacept as an alternative to rituximab","volume":"153","author":"Thompson","year":"2018","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib59","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/1346-8138.15284","article-title":"Clinical significance of serum levels of anti-transcriptional intermediary factor 1-\u03b3 antibody in patients with dermatomyositis","volume":"47","author":"Ikeda","year":"2020","journal-title":"J Dermatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102107_bib60","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/BOR.0000000000000905","article-title":"Biomarkers of disease activity in dermatomyositis","volume":"34","author":"Lu","year":"2022","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102107_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1581323","article-title":"Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies","author":"Groener","year":"2025","journal-title":"Front Immunol [Internet]"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib63","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","article-title":"Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis","volume":"144","author":"Preu\u00dfe","year":"2022","journal-title":"Acta Neuropathol"},{"issue":"11","key":"10.1016\/j.berh.2025.102107_bib64","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2024-225773","article-title":"Pathological autoantibody internalisation in myositis","volume":"83","author":"Pinal-Fernandez","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2025.102107_bib65","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/1346-8138.15117","article-title":"Elevated serum B-cell activating factor levels in patients with dermatomyositis: association with interstitial lung disease","volume":"46","author":"Matsushita","year":"2019","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib66","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-018-1650-8","article-title":"Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis","volume":"20","author":"Kry\u0161t\u016ffkov\u00e1","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13075-014-0454-8","article-title":"Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52\/anti-Ro60 autoantibodies","volume":"16","author":"Kry\u0161t\u016ffkov\u00e1","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib68","doi-asserted-by":"crossref","first-page":"247","DOI":"10.14336\/AD.2020.0410","article-title":"The role of immune cells in the pathogenesis of idiopathic inflammatory myopathies","volume":"12","author":"Zhao","year":"2021","journal-title":"Aging Dis"},{"key":"10.1016\/j.berh.2025.102107_bib69","article-title":"Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/RHU.0000000000002151","article-title":"Rituximab treatment in adult patients with idiopathic inflammatory myositis: a systematic review and meta-analysis","volume":"31","author":"Rojas","year":"2025","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.berh.2025.102107_bib71","article-title":"Systematic review of safety and efficacy of Second- and third-generation CD20-Targeting biologics in treating immune-mediated disorders","volume":"12","author":"Kaegi","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib72","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","article-title":"A review of obinutuzumab (GA101), a novel type II Anti-CD20 monoclonal antibody, for the treatment of patients with B-Cell malignancies","volume":"34","author":"Tobinai","year":"2017","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib73","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2021-221756","article-title":"Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series","volume":"81","author":"Kvacskay","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1142\/S2661341719300040","article-title":"Cyclophosphamide versus obinutuzumab for the treatment of Anti-MDA5 positive inflammatory myopathy with interstitial lung disease: a study protocol and literature review","volume":"19","author":"So","year":"2019","journal-title":"J Clin Rheumatol Immunol"},{"key":"10.1016\/j.berh.2025.102107_bib75","article-title":"Therapeutic potential of Imvotamab, a CD20-Targeted bispecific IgM T cell engager, for the treatment of refractory autoimmune disease patients","year":"2025","journal-title":"ACR Meeting Abstracts"},{"key":"10.1016\/j.berh.2025.102107_bib76","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/annrheumdis-2024-eular.3799","article-title":"Pos1062 therapeutic potential of Imvotamab, A Cd20-Targeted bispecific Igm T cell engager, for the treatment of refractory autoimmune disease patients","volume":"83","author":"Domingo-Gonzalez","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2025.102107_bib77","article-title":"Current strategies to improve chimeric antigen receptor T (CAR-T) cell persistence","volume":"16","author":"Ghorai","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib78","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2025.102107_bib79","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/rheumatology\/kead616","article-title":"Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases","volume":"63","author":"Lyu","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"18","key":"10.1016\/j.berh.2025.102107_bib80","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib81","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.berh.2025.102107_bib82","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.berh.2025.102107_bib83","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-Targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102107_bib84","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"10379","key":"10.1016\/j.berh.2025.102107_bib85","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.berh.2025.102107_bib86","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.berh.2025.102107_bib87","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.berh.2025.102107_bib88","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2024-1115","article-title":"Role of CD19 chimeric antigen receptor T cell therapy in idiopathic inflammatory myopathies","author":"Aggarwal","year":"2025","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2025.102107_bib89","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/jama.2024.1011","article-title":"FDA adds boxed warning to CAR T-Cell therapies, but says benefits outweigh risks of secondary cancers","volume":"331","author":"Suran","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2025.102107_bib90","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"issue":"1\u20132","key":"10.1016\/j.berh.2025.102107_bib91","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jneuroim.2012.04.006","article-title":"The expression of BAFF in the muscles of patients with dermatomyositis","volume":"249","author":"Baek","year":"2012","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib92","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2024.04.060","article-title":"Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: a retrospective observational study","volume":"91","author":"Liu","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib93","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/rheumatology\/kead281","article-title":"Belimumab treatment of adult idiopathic inflammatory myopathy","volume":"63","author":"Marder","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"25","key":"10.1016\/j.berh.2025.102107_bib94","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","article-title":"Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis","volume":"380","author":"Montalban","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib95","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","article-title":"Long-lived autoreactive plasma cells drive persistent autoimmune inflammation","volume":"7","author":"Hiepe","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2025.102107_bib96","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/ajh.20951","article-title":"The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab","volume":"82","author":"Kuwana","year":"2007","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib97","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaut.2012.05.010","article-title":"Bone marrow of NZB\/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity","volume":"39","author":"Mumtaz","year":"2012","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-016-0283-0","article-title":"Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma","volume":"9","author":"Sanchez","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"4","key":"10.1016\/j.berh.2025.102107_bib99","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/ard-2022-223541","article-title":"Daratumumab as a rescue therapy in severe refractory anti-SRP immune-mediated necrotising myopathy","volume":"82","author":"Landon-Cardinal","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib100","first-page":"460","article-title":"Successful rescue treatment of refractory anti-MDA5 autoantibody positive dermatomyositis with rapidly progressive interstitial lung disease using daratumumab","volume":"42","author":"Chua","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102107_bib101","first-page":"e1","article-title":"Successful rescue therapy with daratumumab in rapidly progressive interstitial lung disease caused by MDA5-Positive dermatomyositis. Chest","volume":"163","author":"Holzer","year":"2023"},{"issue":"9","key":"10.1016\/j.berh.2025.102107_bib102","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJMc2408786","article-title":"BCMA-targeted T-Cell\u2013Engager therapy for autoimmune disease","volume":"391","author":"Hagen","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.berh.2025.102107_bib103","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11926-024-01164-7","article-title":"Recent updates on the pathogenesis of inflammatory myopathies","volume":"26","author":"Musai","year":"2024","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.berh.2025.102107_bib104","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40263-024-01090-3","article-title":"FcRn inhibitor therapies in neurologic diseases","volume":"38","author":"Alfaidi","year":"2024","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.berh.2025.102107_bib105","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.berh.2025.102107_bib106","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Investig"},{"issue":"12","key":"10.1016\/j.berh.2025.102107_bib107","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1093\/rheumatology\/kead298","article-title":"Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy","volume":"62","author":"Julien","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2025.102107_bib108","article-title":"Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2025.102107_bib109","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/annrheumdis-2024-eular.3020","article-title":"Ab0250 A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial of nipocalimab in participants with active idiopathic inflammatory myopathies (Spirea): study design","volume":"83","author":"Najem","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2025.102107_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03955.x","article-title":"Mechanisms of action of immune globulin","volume":"157","author":"Fern\u00e1ndez-Cruz","year":"2009","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.berh.2025.102107_bib111","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/art.10053","article-title":"Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients","volume":"46","author":"Cherin","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"27","key":"10.1016\/j.berh.2025.102107_bib112","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.berh.2025.102107_bib113","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2025.102107_bib114","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf070","article-title":"Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study","author":"Charles-Schoeman","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib115","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.berh.2025.102107_bib116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.autrev.2015.12.003","article-title":"Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases","volume":"15","author":"Cherin","year":"2016","journal-title":"Autoimmun Rev Mars"},{"issue":"8","key":"10.1016\/j.berh.2025.102107_bib117","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.3390\/biomedicines10082036","article-title":"Prevention of Anti-HMGCR immune-mediated necrotising myopathy by C5 complement inhibition in a humanised mouse model","volume":"10","author":"Julien","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.berh.2025.102107_bib118","series-title":"Arthritis and rheumatism","first-page":"S489","article-title":"A pilot study of eculizumab in patients with dermatomyositis","author":"Takada","year":"2002"},{"issue":"12","key":"10.1016\/j.berh.2025.102107_bib119","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3899\/jrheum.180060","article-title":"Complement C5-blocking agent in refractory dermatomyositis","volume":"45","author":"Faguer","year":"2018","journal-title":"J Rheumatol"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:11:51Z","timestamp":1765386711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694225000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1521694225000750"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2025.102107","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies in idiopathic inflammatory myopathies: Advances in treatment and future directions","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2025.102107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102107"}}